[go: up one dir, main page]

WO2012022120A8 - Composé dihydro-pyrazole - Google Patents

Composé dihydro-pyrazole Download PDF

Info

Publication number
WO2012022120A8
WO2012022120A8 PCT/CN2011/001378 CN2011001378W WO2012022120A8 WO 2012022120 A8 WO2012022120 A8 WO 2012022120A8 CN 2011001378 W CN2011001378 W CN 2011001378W WO 2012022120 A8 WO2012022120 A8 WO 2012022120A8
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
dihydropyrazole
formula
dihydropyrazole compounds
isomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2011/001378
Other languages
English (en)
Chinese (zh)
Other versions
WO2012022120A1 (fr
Inventor
张艳
陈俊宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KBP Biosciences Co Ltd
Original Assignee
KBP Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KBP Biosciences Co Ltd filed Critical KBP Biosciences Co Ltd
Priority to CN201180031781.5A priority Critical patent/CN103052632B/zh
Publication of WO2012022120A1 publication Critical patent/WO2012022120A1/fr
Anticipated expiration legal-status Critical
Publication of WO2012022120A8 publication Critical patent/WO2012022120A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Fait l'objet de cette invention un composé dihydro-pyrazole de formule (1a), son sel pharmaceutiquement acceptable et son isomère, son procédé de préparation, ses préparations pharmaceutiques et ses applications. Les substituants de formule (1a) sont tels que définis dans le descriptif. Application : traitement et/ou prévention de lésions rénales, de maladies cardiovasculaires, notamment l'hypertension et/ou les maladies endocriniennes.
PCT/CN2011/001378 2010-08-18 2011-08-18 Composé dihydro-pyrazole Ceased WO2012022120A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201180031781.5A CN103052632B (zh) 2010-08-18 2011-08-18 二氢吡唑类化合物

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN201010256527 2010-08-18
CN201010256527.2 2010-08-18
CN201010549656.0 2010-11-12
CN201010549656 2010-11-12
CN201110080789.2 2011-03-23
CN201110080789 2011-03-23

Publications (2)

Publication Number Publication Date
WO2012022120A1 WO2012022120A1 (fr) 2012-02-23
WO2012022120A8 true WO2012022120A8 (fr) 2013-02-21

Family

ID=45604725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2011/001378 Ceased WO2012022120A1 (fr) 2010-08-18 2011-08-18 Composé dihydro-pyrazole

Country Status (2)

Country Link
CN (1) CN103052632B (fr)
WO (1) WO2012022120A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017064121A1 (fr) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement de la néovascularisation choroïdienne
US20190262363A1 (en) 2016-07-26 2019-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
US20230151425A1 (en) 2020-03-11 2023-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
EP4395785A1 (fr) 2021-08-31 2024-07-10 Inserm (Institut National de la Santé et de la Recherche Scientifique) Méthodes de traitement de la rosacée oculaire

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008020113A1 (de) * 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DE102006050513A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung

Also Published As

Publication number Publication date
WO2012022120A1 (fr) 2012-02-23
CN103052632A (zh) 2013-04-17
CN103052632B (zh) 2014-03-19

Similar Documents

Publication Publication Date Title
IN2014KN00948A (fr)
WO2012019426A8 (fr) Dérivé de phtalazinone, son procédé de préparation et utilisation pharmaceutique
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
WO2012019430A8 (fr) Dérivé de phtalazinone, son procédé de préparation et utilisation pharmaceutique
WO2013100566A8 (fr) Composé de dérivés de carbamate d'alkyle phényle et composition pharmaceutique en contenant
WO2012118308A3 (fr) Composition contenant un dérivé de pyrazole destinée à prévenir et à traiter les maladies cardiovasculaires
WO2012122340A8 (fr) Activateurs de guanylate cyclase solubles
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
MD20140072A2 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
HRP20191617T1 (hr) Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
WO2013004995A8 (fr) Composés pyrimidinones et leur utilisation
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
HK1255500A1 (zh) 氧固醇及其使用方法
WO2013112959A8 (fr) Composés antifibrotiques et leurs utilisations
WO2013009527A3 (fr) Inhibiteurs du facteur ixa
WO2012135615A3 (fr) Enopeptines, utilisations de celles-ci, et procédés de synthèse de celles-ci
ZA201802312B (en) A group of compounds used for the treatment or prevention of hyperuricemia or gout
WO2009140341A3 (fr) Compositions d'atorvastatine
WO2013177534A3 (fr) Nouveaux dérivés d'acide salicylique, sel de qualité pharmaceutique correspondant, composition et procédé d'utilisation correspondants
WO2014036502A8 (fr) Composés de tétracyclines
WO2009015368A3 (fr) Inhibiteurs multikinase à utiliser dans le traitement du cancer
EA201291014A1 (ru) Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция
MX2014003701A (es) Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio.
WO2010121675A3 (fr) Thiazolyl-benzimidazoles
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180031781.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11817648

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11817648

Country of ref document: EP

Kind code of ref document: A1